In the article titled “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma” [1], the survival data for the Tim-3+ TIL and Tim-3- TIL groups was mistakenly reversed by the authors during manuscript preparation. The following sections should be corrected. (i)The abstract section should be corrected from:
“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3+ TILs) exhibited poor outcomes than those with Tim-3- TILs (). The median survival times of these patients were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”
To:
“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3+ TILs) exhibited poor outcomes than those with Tim-3- TILs (). The median survival times of these patients were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.” (ii)Section 3.4, “Prognostic value of Tim-3+ TILs and exhausted Tim-3+ CD8+ T cells in DLBCL,” should be corrected from:
“The median survival times for patients with Tim-3+ TILs and Tim-3- TILs were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”
To:
“The median survival times for patients with Tim-3+ TILs and Tim-3- TILs were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.”